The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
<h4>Background</h4>The introduction of specific BCR-ABL inhibitors in chronic myelogenous leukemia therapy has entirely mutated the prognosis of this hematologic cancer from being a fatal disorder to becoming a chronic disease. Due to the probable long lasting treatment with tyrosine-kin...
Guardado en:
Autores principales: | Adriana Borriello, Ilaria Caldarelli, Maria Assunta Basile, Debora Bencivenga, Annunziata Tramontano, Silverio Perrotta, Fulvio Della Ragione, Adriana Oliva |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/16c48b6ed8714db89955d42804853f88 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Generation of two multipotent mesenchymal progenitor cell lines capable of osteogenic, mature osteocyte, adipogenic, and chondrogenic differentiation
por: Matthew Prideaux, et al.
Publicado: (2021) -
EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.
por: Silverio Perrotta, et al.
Publicado: (2010) -
Alteration of active and repressive histone marks during adipogenic differentiation of porcine mesenchymal stem cells
por: Joanna Stachecka, et al.
Publicado: (2021) -
Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
por: Alice Barbarin, et al.
Publicado: (2020) -
ROLE OF MESENCHYMAL MULTIPOTENT STROMAL CELLS IN REMODELING OF BONE DEFECTS
por: M. V. Kiselevsky, et al.
Publicado: (2018)